Nicotinamide methylation in patients with cirrhosis

Area of Science:

• Hepatology
• Metabolic Biochemistry
• Pharmacology

Background:

• Methylation is crucial for substance transformation, primarily in the liver.
• Hepatic diseases significantly impact methylation processes.
• Nicotinamide methylation is a key transmethylation pathway affected by liver function.

Purpose of the Study:

• To investigate the impact of cirrhosis on nicotinamide methylation efficiency.
• To compare N-methyl-nicotinamide levels and excretion in cirrhosis patients versus healthy controls.
• To assess if hepatic disease impairs the body's ability to methylate nicotinamide.

Main Methods:

• Measured basal serum N-methyl-nicotinamide in 16 controls and 29 cirrhosis patients.
• Administered oral nicotinamide to assess serum levels and urinary excretion over 5 and 24 hours.
• Compared N-methyl-nicotinamide pharmacokinetics between control and patient groups.

Main Results:

• Cirrhosis patients exhibited significantly higher basal serum N-methyl-nicotinamide levels.
• Post-nicotinamide load, both urinary excretion and serum levels of N-methyl-nicotinamide were elevated in cirrhosis patients.
• The study found higher excretion and serum concentration-time curves in cirrhosis patients.

Conclusions:

• Cirrhosis does not impair the overall efficiency of nicotinamide methylation.
• Despite altered basal levels and excretion patterns, the liver maintains its capacity for nicotinamide methylation in cirrhosis.
• Findings suggest a complex metabolic adaptation rather than a functional deficit in methylation capacity.